Axa bought a new position in shares of Stemline Therapeutics Inc (NASDAQ:STML) during the first quarter, Holdings Channel reports. The fund bought 434,183 shares of the biopharmaceutical company’s stock, valued at approximately $3,712,000.

Other large investors have also recently bought and sold shares of the company. Ladenburg Thalmann Financial Services Inc. boosted its stake in Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 11,300 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical company’s stock worth $701,000 after buying an additional 4,800 shares during the last quarter. Candriam Luxembourg S.C.A. purchased a new stake in Stemline Therapeutics during the third quarter worth approximately $2,783,000. State Street Corp boosted its stake in Stemline Therapeutics by 9.2% in the fourth quarter. State Street Corp now owns 251,804 shares of the biopharmaceutical company’s stock worth $2,694,000 after buying an additional 21,296 shares during the last quarter. Finally, J. Goldman & Co LP purchased a new stake in Stemline Therapeutics during the fourth quarter worth approximately $2,139,000. 37.76% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)

Stemline Therapeutics Inc (NASDAQ:STML) remained flat at $7.65 on Friday. The company’s stock had a trading volume of 57,602 shares. The firm’s market cap is $178.83 million. The stock has a 50-day moving average of $8.30 and a 200-day moving average of $9.50. Stemline Therapeutics Inc has a 52 week low of $5.50 and a 52 week high of $14.60.

Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by $0.22. Stemline Therapeutics had a negative return on equity of 50.06% and a negative net margin of 4,058.44%. The company had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.30 million. Analysts forecast that Stemline Therapeutics Inc will post ($2.26) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/06/09/axa-invests-3-71-million-in-stemline-therapeutics-inc-stml.html.

STML has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $34.00 target price on shares of Stemline Therapeutics in a research report on Tuesday, March 28th. Zacks Investment Research raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 9th. Wedbush reissued an “outperform” rating and set a $11.00 target price on shares of Stemline Therapeutics in a research report on Friday, March 17th. Cowen and Company reissued a “buy” rating on shares of Stemline Therapeutics in a research report on Friday, May 12th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $16.00 price target on shares of Stemline Therapeutics in a report on Thursday, May 25th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $29.17.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Want to see what other hedge funds are holding STML? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stemline Therapeutics Inc (NASDAQ:STML).

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.